For the latest openings visit the Careers section of our website CPL Biologicals launches Cadiflu-S,World`s First Virus Like Particle(VLP) Vaccine for Seasonal Influenza
The public at large is cautioned of fraudulent activities and false commitments using the name of Cadila.

News & Events

  • CPL Biologicals launches Cadiflu-S, World’s First Virus Like Particle (VLP) Vaccine for Seasonal Influenza Read More >>


Cadila Pharmaceuticals believes in forging scientific collaborations with world class institutions to jointly develop treatments for hitherto unmet medical needs.

  • Alliances_03In 2006, Cadila Pharmaceuticals entered into a joint venture with Apollo Hospitals Group to manage Apollo Hospitals, Ahmedabad Over the last decade, it has been recognized as a center of excellence and has emerged as a trusted destination for the patients in the region
  • steIn 2008, Cadila Pharmaceuticals formed a JV with StemCyte Inc. USA, organization dedicated to the collection, processing, testing and storage of both – private and public umbilical cord blood units and its therapeutic applications.
  • novavaxIn 2009, Cadila Pharmaceuticals acquired a significant stake in Novavax Inc., USA, a clinical-stage biopharmaceutical company to form a joint venture, CPL Biologicals, which develops and produces vaccines based on virus-like-particle (VLP) methodology.
  • helperbyIn 2013, Cadila Pharmaceuticals and UK-based antibiotics discovery major, Helperby Therapeutics signed a joint agreement on Antibiotic Drug Resistance Research and Development, a major breakthrough in the fight against antibiotic resistance with the discovery of patented ‘resistance breaker’ compounds.
  • helperbyIn 2014, Cadila Pharmaceuticals entered into R & D collaboration with Sweden based Respiratorius AB to develop a novel bronchodilator molecule, with a unique mechanism, for the treatment of COPD.
  • helperbyIn 2015, Cadila Pharmaceuticals signed Product development and license agreement with Moberg AB, Sweden for Bupivacaine lozenges for pain management in oral mucositis patients, following radiation therapy or chemotherapy in variety of cancer patients.
  • helperby
    In 2015, Cadila Pharmaceuticals entered in to Co-development agreement with Axelar for the formulation development and clinical trial treatment of non-small cell lung cancer (NSCLC).
  • helperbyIn 2016, Cadila Pharmaceuticals entered in to collaboration agreement with Oncology Venture Sweden AB (OV) for novel Liposomal formulation of cisplatin treatment for treating solid tumours.
  • helperbyIn 2016, Cadila Pharmaceuticals entered in to research collaboration agreement with Arecor, UK for development of differentiated long acting insulin analogue Glargine.
  • helperbyIn 2017, Cadila Pharmaceuticals entered in to collaboration with Aplagon Oy, Finland for development and commercialization of heparin proteoglycan mimetic for use in certain vascular surgeries.
Counterfeit Drugs: In case of any information on /or availability of counterfeit products... Read More © 2018 Cadila Pharmaceuticals all right reserved
Corporate identification No : U24231GJ1991PLC015132
Cadila Pharmaceuticals